Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges

European Journal of Medicinal Chemistry

Volumn 95, Issue , 2015, Pages 35-40

  Yu, Bin ^a   Yu, Zhiqiang ^b   Qi, Ping Ping ^a   Yu, De Quan ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer drug; CFI 400945; Kinase selectivity; Spirooxindoles

Indexed keywords

ANTINEOPLASTIC AGENT; CFI 400945; INDOLE DERIVATIVE; POLO LIKE KINASE 4; PROTEIN SERINE THREONINE KINASE; SPIROOXINDOLE DERIVATIVE; UNCLASSIFIED DRUG; 2-(3-(4-((2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-INDAZOL-6-YL)-5'-METHOXYSPIRO(CYCLOPROPANE-1,3'-INDOLIN)-2'-ONE; INDAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CENTRIOLE; CHROMOSOMAL INSTABILITY; COMPETITIVE INHIBITION; CYCLOPROPANATION; CYTOKINESIS; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG PROGRAM; DRUG PROTEIN BINDING; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; RING OPENING; RNA INTERFERENCE; SUZUKI REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; NEOPLASMS; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; INDAZOLES; INDOLES; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924801947     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.03.020     Document Type: Short Survey

References (34)

1. H. Zhao I. Akritopoulou-Zanze When analoging is not enough: scaffold discovery in medicinal chemistry Expert Opin. Drug Discov. 5 2010 123 134
2. P.J. Hajduk W.R.J.D. Galloway D.R. Spring Drug discovery: a question of library design Nature 470 2011 42 43
3. M.E. Welsch S.A. Snyder B.R. Stockwell Privileged scaffolds for library design and drug discovery Curr. Opin. Chem. Biol. 14 2010 347 361
4. F.-A. Kang Z. Sui A diversity-oriented-synthesis protocol for scaffold discovery based on a general synthetic route to spirocycles Tetrahedron Lett. 52 2011 4204 4206
5. Y. Zheng C.M. Tice S.B. Singh The use of spirocyclic scaffolds in drug discovery Bioorg. Med. Chem. Lett. 24 2014 3673 3682
6. C.V. Galliford K.A. Scheidt Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents Angew. Chem. Int. Ed. 46 2007 8748 8758
7. B. Yu D.-Q. Yu H.-M. Liu Spirooxindoles: promising scaffolds for anticancer agents Eur. J. Med. Chem. 2015
8. P.B. Sampson Y. Liu B. Forrest G. Cumming S.-W. Li N.K. Patel L. Edwards R. Laufer M. Feher F. Ban D.E. Awrey G. Mao O. Plotnikova R. Hodgson I. Beletskaya J.M. Mason X. Luo V. Nadeem X. Wei R. Kiarash B. Madeira P. Huang T.W. Mak G. Pan H.W. Pauls The discovery of polo-like kinase 4 inhibitors: identification of (1 R,2 S)-2-(3-((E)-4-(((cis)-2,6-dimethylmorpholino)methyl)styryl)-1 H-indazol-6-yl)-5g2-methoxyspiro[cyclopropane-1,3g2-indolin]-2g 2-one (CFI-400945) as a potent, orally active antitumor agent J. Med. Chem. 58 2015 147 169
9. D.M. Glover I.M. Hagan Á.A.M. Tavares Polo-like kinases: a team that plays throughout mitosis Genes. Dev. 12 1998 3777 3787
10. D.M. Lowery D. Lim M.B. Yaffe Structure and function of polo-like kinases Oncogene 24 2005 248 259
11. P. Schöffski Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology Oncologist 14 2009 559 570
12. E.F. Johnson K.D. Stewart K.W. Woods V.L. Giranda Y. Luo Pharmacological and functional comparison of the polo-like kinase family:ginsight into inhibitor and substrate specificity Biochemistry 46 2007 9551 9563
13. C. McInnes M. Mezna P.M. Fischer Progress in the discovery of polo-like kinase inhibitors Curr. Top. Med. Chem. 5 2005 181 197
14. S.M. Lens E.E. Voest R.H. Medema Shared and separate functions of polo-like kinases and aurora kinases in cancer Nat. Rev. Cancer 10 2010 825 841
15. M. Kothe D. Kohls S. Low R. Coli A.C. Cheng S.L. Jacques T.L. Johnson C. Lewis C. Loh J. Nonomiya A.L. Sheils K.A. Verdries T.A. Wynn C. Kuhn Y.-H. Ding Structure of the catalytic domain of human polo-like kinase 1 Biochemistry 46 2007 5960 5971
16. M. Ahn Y.-H. Han J.-E. Park S. Kim W.C. Lee S.J. Lee P. Gunasekaran C. Cheong S.Y. Shin H.-Y. Kim E.K. Ryu R.N. Murugan N.-H. Kim J.K. Bang A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1 J. Med. Chem. 58 2015 294 304
17. M.O. Duffey T.J. Vos R. Adams J. Alley J. Anthony C. Barrett I. Bharathan D. Bowman N.J. Bump R. Chau C. Cullis D.L. Driscoll A. Elder N. Forsyth J. Frazer J. Guo L. Guo M.L. Hyer D. Janowick B. Kulkarni S.-J. Lai K. Lasky G. Li J. Li D. Liao J. Little B. Peng M.G. Qian D.J. Reynolds M. Rezaei M.P. Scott T.B. Sells V. Shinde Q.J. Shi M.D. Sintchak F. Soucy K.T. Sprott S.G. Stroud M. Nestor I. Visiers G. Weatherhead Y. Ye N. D'Amore Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of polo-like kinase 1 (MLN0905) J. Med. Chem. 55 2011 197 208
18. R. Habedanck Y.-D. Stierhof C.J. Wilkinson E.A. Nigg The Polo kinase Plk4 functions in centriole duplication Nat. Cell. Biol. 7 2005 1140 1146
19. C.O. Rosario M.A. Ko Y.Z. Haffani R.A. Gladdy J. Paderova A. Pollett J.A. Squire J.W. Dennis C.J. Swallow Plk4 is required for cytokinesis and maintenance of chromosomal stability Proc. Natl. Acad. Sci. USA. 107 2010 6888 6893
20. K. Kazazian R. Xu F. Zih C. Rosario C.J. Swallow Polo-like kinase 4 (Plk4) promotes cancer cell invasion J. Am. Coll. Surg. 217 2013 S128
21. J. Sillibourne M. Bornens Polo-like kinase 4: the odd one out of the family Cell. Div. 5 2010 25 33
22. M. Bettencourt-Dias A. Rodrigues-Martins L. Carpenter M. Riparbelli L. Lehmann M. Gatt N. Carmo F. Balloux G. Callaini D. Glover SAK/PLK4 is required for centriole duplication and flagella development Curr. Biol. 15 2005 2199 2207
23. R. Laufer B. Forrest S.-W. Li Y. Liu P. Sampson L. Edwards Y. Lang D.E. Awrey G. Mao O. Plotnikova G. Leung R. Hodgson I. Beletskaya J.M. Mason X. Luo X. Wei Y. Yao M. Feher F. Ban R. Kiarash E. Green T.W. Mak G. Pan H.W. Pauls The discovery of PLK4 inhibitors: (E)-3-((1 H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents J. Med. Chem. 56 2013 6069 6087
24. A. Flemming Cancer: PLK4 inhibitor shows potent antitumour activity Nat. Rev. Drug. Discov. 13 2014 654
25. Jacqueline M. Mason Dan C.-C. Lin X. Wei Y. Che Y. Yao R. Kiarash David W. Cescon Graham C. Fletcher Donald E. Awrey Mark R. Bray G. Pan Tak W. Mak Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent Cancer Cell. 26 2014 163 176
26. C.W. Brownlee J.E. Klebba D.W. Buster G.C. Rogers The protein phosphatase 2A regulatory subunit twins stabilizes Plk4 to induce centriole amplification J. Cell. Biol. 195 2011 231 243
27. A. Puklowski Y. Homsi D. Keller M. May S. Chauhan U. Kossatz V. Grunwald S. Kubicka A. Pich M.P. Manns I. Hoffmann P. Gonczy N.P. Malek The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication Nat. Cell. Biol. 13 2011 1004 1009
28. A. Holland W. Lan S. Niessen H. Hoover D. Cleveland Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability J. Cell. Biol. 188 2010 191 198
29. For more information about clinical trials of CFI-400945 fumarate, please refer to the National Cancer Institute website (http://www.cancer.gov/drugdictionary?cdridCombining double low line754001).
30. P.B. Sampson Y. Liu N.K. Patel M. Feher B. Forrest S.-W. Li L. Edwards R. Laufer Y. Lang F. Ban D.E. Awrey G. Mao O. Plotnikova G. Leung R. Hodgson J. Mason X. Wei R. Kiarash E. Green W. Qiu N.Y. Chirgadze T.W. Mak G. Pan H.W. Pauls The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,32[3 H[indol]-22(12 H)-ones as orally bioavailable antitumor agents J. Med. Chem. 58 2015 130 146
31. D.Y.K. Chen R.H. Pouwer J.-A. Richard Recent advances in the total synthesis of cyclopropane-containing natural products Chem. Soc. Rev. 41 2012 4631 4642
32. F.Z. Gaugaz M. Redondo-Horcajo I. Barasoain J.F. Diáz A. Cobos-Correa M. Kaufmann K.-H. Altmann The impact of cyclopropane configuration on the biological activity of cyclopropyl-epothilones ChemMedChem 9 2014 2227 2232
33. Andrew J. Holland Don W. Cleveland Polo-like kinase 4 inhibition: a strategy for cancer therapy? Cancer Cell. 26 2014 151 153
34. N.E. Sharpless R.A. DePinho The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug. Discov. 5 2006 741 754